|
sGFAP
|
sNfL
|
|---|
|
Time between baseline visit and
|
Patient group (n)
|
ηρ2 for interaction, p
|
Std. effect size
|
β (95% CI)
|
p
|
ηρ2 for interaction, p
|
Std. effect size
|
β (95% CI)
|
p
|
|---|
|
First manifestation of diseasea
|
AQP4-IgG+ (33)
|
0.05, p = 0.14
|
0.18
|
0.20 (− 0.84–1.24)
|
0.70
|
0.02, p = 0.40
|
− 1.27
|
− 1.37 (− 2.92–0.19)
|
0.08
|
|
MOG-IgG+ (16)
|
− 0.96
|
− 1.10 (− 2.58–0.38)
|
0.14
|
− 1.99
|
− 2.14 (− 3.68 to − 0.60)
|
0.008
|
|
Last attacka
|
AQP4-IgG+ (33)
|
0.03, p = 0.25
|
0.41
|
0.46 (− 0.55–1.47)
|
0.37
|
< 0.01, p = 0.80
|
− 1.22
|
− 1.32 (− 2.88–0.25)
|
0.10
|
|
MOG-IgG+ (16)
|
-0.47
|
− 0.53 (− 1.96–0.91)
|
0.46
|
− 0.99
|
− 1.08 (− 2.63–0.48)
|
0.17
|
- aLinear models using log-transformed sGFAP and sNfL and time interval values, adjusted for age. Furthermore, an interaction term of baseline sGFAP or sNFL (log-transformed) and group was included to assess the statistical significance of inter group differences
- AQP4-IgG aquaporin-4 immunoglobulin G, β regression coefficient, CI confidence interval, ηρ2 partial eta-squared, MOG-IgG myelin oligodendrocyte protein immunoglobulin G, n number, NMOSD neuromyelitis optica spectrum disorders, sGFAP serum glial fibrillary acidic protein, sNfL serum neurofilament light chain protein, std. effect size standardized effect size
